Home Cart Sign in  
Chemical Structure| 356559-20-1 Chemical Structure| 356559-20-1

Structure of SB-525334
CAS No.: 356559-20-1

Chemical Structure| 356559-20-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SB-525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.

Synonyms: TGF-β RI Kinase Inhibitor VIII

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SB-525334

CAS No. :356559-20-1
Formula : C21H21N5
M.W : 343.42
SMILES Code : CC1=CC=CC(=N1)C1=C(N=C(N1)C(C)(C)C)C1=CC2=C(C=C1)N=CC=N2
Synonyms :
TGF-β RI Kinase Inhibitor VIII
MDL No. :MFCD11045307
InChI Key :DKPQHFZUICCZHF-UHFFFAOYSA-N
Pubchem ID :9967941

Safety of SB-525334

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • TGFβRI/ALK5

    TGFβR1(ALK5), IC50:14.3 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Healthy NK cells 2 µM 1-hour pre-incubation Prevented POD1 plasma-induced NK cell dysfunction, maintained NKG2D, DNAM-1, CD132 expression and IFNγ production Int J Mol Sci. 2022 Nov 23;23(23):14608
Rabbit bone marrow mesenchymal stem cells (R-BMSCs) 14.3 nM 4 hours To evaluate the effect of SB-525334 on the survival rate of R-BMSCs, results showed that SB-525334 had no significant effect on the survival rate of R-BMSCs under 48˚C microwave treatment. Mol Med Rep. 2020 Aug;22(2):906-914
VX2 cells 14.3 nM 4 hours To evaluate the effect of SB-525334 on the survival rate of VX2 cells, results showed that SB-525334 significantly reduced the survival rate of VX2 cells under 48˚C microwave treatment. Mol Med Rep. 2020 Aug;22(2):906-914
Immortalized human hepatic stellate cells (hTERT-HSC) 1 µM 48 hours SB52 inhibits TGF-β1-induced activation of hTERT-HSC. PLoS One. 2018 Jul 20;13(7):e0201044
Human primary hepatic stellate cells 1 µM 48 hours SB52 induces upregulation of Nrf2 and Nqo1, efficiently inhibiting the TGF-β1 effect. PLoS One. 2018 Jul 20;13(7):e0201044
PASMCs from familial iPAH patients 1 µM 6 days To evaluate the effect of SB525334 on TGF-β1-mediated proliferation of PASMCs from familial iPAH patients. Results showed that SB525334 significantly inhibited TGF-β1-mediated proliferation. Am J Pathol. 2009 Feb;174(2):380-9
Lgr5+CD44+EpCAM+ colorectal cancer stem cells 2 μg/mL 6 hours SB525334 inhibited the TGF-β1 pathway, downregulated TGF-β1, p-Smad2/3, and Snail expression, while upregulated Smad4, E-cad, and ZO-1 expression, thereby suppressing KLF4 overexpression-induced mesenchymal phenotypes and stemness properties. J Cell Mol Med. 2020 Jan;24(2):1866-1877
Human umbilical vein endothelial cells (HUVECs) 10 µM 72 hours To investigate the role of TGF-β receptor ALK5 signaling in HUVEC morphology under shear stress. Results showed that SB525334 inhibition of ALK5 signaling led to disruption of the HUVEC monolayer and increased apoptosis. Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2608-17
Rat tubular epithelial cells (NRK52E) 1 µM 72 hours SB 525334 treatment blocked TGF-β-induced upregulation of ADAM10, ADAM17, ADAM12, and ADAM19 gene expression. Am J Pathol. 2013 Dec;183(6):1885-1896
SU-DIPG-IV cells 50 µM 72 hours Evaluate the inhibitory effect of SB525334 on SU-DIPG-IV cell growth, showing significant inhibition at 50 µM dose Sci Rep. 2020 Apr 9;10(1):6140
SF8628 cells 50 µM 72 hours Evaluate the inhibitory effect of SB525334 on SF8628 cell growth, showing significant inhibition at 50 µM dose Sci Rep. 2020 Apr 9;10(1):6140
CD44+ leader cells 5 µM from day 0 thoursoughours day 3 post-injury To investigate the role of endogenous TGF β signaling in CD44+ leader cells during wound healing. Results showed that endogenous TGF β signaling had no effect on leader cell-directed wound closure. Exp Eye Res. 2021 Dec;213:108829

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats High-salt diet-induced endothelial dysfunction model Oral (via drinking water) 10 mg/kg/day Once daily for 2 days SB525334 reduced high-salt diet-induced Smad2 phosphorylation to levels observed in rats on the low-salt diet and prevented the downstream signaling events induced by the high-salt diet Hypertension. 2013 Nov;62(5):951-6
C57/BL6 mice Unilateral ureteral obstruction (UUO) model Oral gavage 10 mg/kg/day Once daily for 7 days SB 525334 significantly reduced the gene expression of ADAM10, ADAM17, ADAM12, and ADAM19 in the UUO model and decreased the enzymatic activity of ADAM10 and ADAM17. Am J Pathol. 2013 Dec;183(6):1885-1896
New Zealand rabbits Osteosarcoma model Ear vein injection 21.45 nM, 100 µL 21 days To evaluate the therapeutic effect of SB-525334 on osteosarcoma, results showed that microwave treatment combined with SB-525334 significantly reduced tumor volume. Mol Med Rep. 2020 Aug;22(2):906-914
Sprague-Dawley rats MCT-induced pulmonary arterial hypertension model Oral 3 or 30 mg/kg Daily dosing until day 35 To evaluate the therapeutic effect of SB525334 on MCT-induced pulmonary arterial hypertension. Results showed that SB525334 significantly reversed elevated pulmonary arterial pressure and inhibited right ventricular hypertrophy. Am J Pathol. 2009 Feb;174(2):380-9
Chick embryos Ex vivo mock-cataract-surgery model In vitro culture treatment 5μM From day 0 through day 3 post-injury To investigate the role of endogenous TGF β signaling in the fibrotic response of CD44+ leader cells in the rigid wound environment. Results showed that endogenous TGF β signaling induced FN-EDA and pro-collagen I production by leader cells and promoted their transition to an αSMA+ myofibroblast phenotype in the rigid environment. Exp Eye Res. 2021 Dec;213:108829

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.91mL

0.58mL

0.29mL

14.56mL

2.91mL

1.46mL

29.12mL

5.82mL

2.91mL

References

 

Historical Records

Categories